Rituximab Biosimilar Immunological Preparation
A mixed immunological product containing rituximab monoclonal antibodies used for treating non-Hodgkin lymphoma and rheumatoid arthritis. Classified under HTS 3002.14.0010 as it is an immunological product containing monoclonal antibodies, not put up in measured doses or retail packings. It consists of multiple components including the antibody and stabilizers for therapeutic use.
Import Duty Rates by Country of Origin
Alternative Classifications
This product could be classified differently depending on its characteristics or intended use.
If not containing monoclonal antibodies
Products with other immunological agents but without monoclonals fall under the general immunological products subheading.
If put up in measured doses for retail sale
Retail-packaged versions shift to the measured doses category regardless of monoclonal content.
If classified as hormones rather than immunological product
Certain biotech peptides might be reclassified under hormones if primary function is not immunological.
Not sure which classification is right?
Our AI classifier can analyze your specific product and recommend the correct HTS code with confidence.
Import Tips & Compliance
• Verify product contains monoclonal antibodies via certificate of analysis; ensure biotech origin documentation
• Comply with FDA biologics import requirements including lot release and proper cold chain validation
• Avoid misclassification as unmixed by confirming mixture of antibody with excipients; declare exact composition
Related Products under HTS 3002.14.00.10
Trastuzumab Emtansine Mixture
Immunological preparation mixing trastuzumab monoclonal antibody with emtansine for HER2-positive breast cancer treatment. Falls under HTS 3002.14.0010 due to monoclonal antibody content in a mixed, non-retail bulk form for hospital use. Includes buffers and stabilizers as mixed components.
Pembrolizumab Bulk Immunological Product
Mixed preparation of pembrolizumab (Keytruda) monoclonal antibody for immunotherapy in melanoma and lung cancer. HTS 3002.14.0010 applies to this bulk mixed form containing the antibody with formulation excipients, not for retail. Used in clinical or manufacturing settings.
Bevacizumab Biosimilar Mixture
Bulk mixed immunological product with bevacizumab monoclonal antibodies targeting VEGF for colorectal cancer therapy. Classified in HTS 3002.14.0010 as a mixed monoclonal immunological product not in retail form. Contains antibody, surfactants, and buffers.
Infliximab Therapeutic Mixture
Mixed immunological preparation containing infliximab monoclonal antibodies for autoimmune diseases like Crohn's. HTS 3002.14.0010 for bulk mixed monoclonal products used in biotech manufacturing. Includes polysorbate and histidine buffers.
Adalimumab Reference Product Bulk
Bulk mixed form of adalimumab (Humira) monoclonal antibody for rheumatoid arthritis treatment. Falls under HTS 3002.14.0010 as mixed immunological product with monoclonal antibodies, supplied for further dilution. Not in measured retail doses.
Nivolumab Immunotherapy Preparation
Mixed nivolumab monoclonal antibody product for PD-1 inhibition in cancer immunotherapy. HTS 3002.14.0010 classification for bulk mixed immunological containing monoclonals for clinical trials. Includes sucrose stabilizer and buffer system.